MK-0777

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H22FN7O
Molecular Weight	395.4334
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCN1N=CN=C1COC2=NN3C(C=C2C(C)(C)C)=NN=C3C4=CC=CC=C4F

InChI

InChIKey=QKIWQBLNTSQOLY-UHFFFAOYSA-N

InChI=1S/C20H22FN7O/c1-5-27-17(22-12-23-27)11-29-19-14(20(2,3)4)10-16-24-25-18(28(16)26-19)13-8-6-7-9-15(13)21/h6-10,12H,5,11H2,1-4H3

HIDE SMILES / InChI

Molecular Formula	C20H22FN7O
Molecular Weight	395.4334
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21145041 | https://www.ncbi.nlm.nih.gov/pubmed/21890585 | https://www.ncbi.nlm.nih.gov/pubmed/19779131

MK 0777 is a selective GABAA α2/3 receptor partial agonist, for potential use in the treatment of Schizophrenia, Anxiety Disorder, and Generalized Anxiety Disorder. MK-0777 is functionally selective for the α2 and α3 subunits, with virtually no activity for the α1 and α5 subunits. Therefore, MK-0777 cause less sedation, interact less with alcohol, and exhibit less abuse potential and physical dependence than benzodiazepines. Unfortunately, in clinical trials, MK-0777 has little benefit for cognitive impairments in people with schizophrenia and anxiety disorder.

CNS Activity

Originator

Approval Year

PubMed

Title	Date	PubMed
7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine: a functionally selective gamma-aminobutyric acid(A) (GABA(A)) alpha2/alpha3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models.	2005 Nov 17	16279764
TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates.	2006 Jan	16183706
Metabolism and disposition of a potent and selective GABA-Aalpha2/3 receptor agonist in healthy male volunteers.	2006 Jun	16510541
Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers.	2007 Jun	17092968
In vivo characterization and dynamic receptor occupancy imaging of TPA023B, an alpha 2/alpha 3/alpha 5 subtype selective gamma-aminobutyric acid-a partial agonist.	2008 Jul 15	18339360
Pharmacological Properties of DOV 315,090, an ocinaplon metabolite.	2008 Jun 13	18554397
Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023.	2009	20230761
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.	2011 Mar 1	21145041

Patents

Sample Use Guides

In Vivo Use Guide

3 mg b.i.d. or 8 mg b.i.d.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:30:51 GMT 2023` Edited by `admin` on `Fri Dec 15 15:30:51 GMT 2023`
Record UNII	1FI3KTC550
Record Status	`Validated (UNII)`
Record Version